MAZE — Maze Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1842295 ·
Last close
$26.35
Market Cap
$1.46B
52W High
$53.65
52W Low
$23.76
ADV30
684,983
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,000,000 | — | -26,553,000 | -24,208,000 | 419,710,000 | 198,766,000 | 78,009,000 |
| Dec 2025 | 0 | — | -38,059,000 | -34,568,000 | 397,127,000 | 189,247,000 | 42,161,000 |
| Sep 2025 | 0 | — | -32,965,000 | -30,087,000 | 422,058,000 | 316,773,000 | 42,622,000 |
| Jun 2025 | 0 | — | -36,474,000 | -33,679,000 | 303,519,000 | 264,541,000 | 41,281,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-111,940,000
Investing CF
$-170,962,000
Financing CF
$275,337,000
CapEx
$-794,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-489,547,000
Inventory
—
Receivables
—
ST Investments
$152,670,000
EBIT TTM
$-142,899,000
Pretax Income TTM
$-131,120,000
Interest Exp TTM
—
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,000,000
EBITDA
$-131,888,000
Free Cash Flow
$-81,703,128
Enterprise Value
$1,135,641,856
Total Cash
$352,382,016
Total Debt
$61,223,000
Shares Out
55,345,261
Trailing EPS
$-2.35
Book Value
$6.93
ROE
-38.7%
ROA
-22.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -142,899,000 | -131,120,000 | 397,127,000 | 42,161,000 | — | -111,940,000 |
| Dec 2024 | 167,500,000 | 57,586,000 | 52,231,000 | 240,542,000 | 551,725,000 | — | 75,954,000 |
| Dec 2023 | 0 | -98,551,000 | -100,415,000 | 71,504,000 | 445,352,000 | — | -86,827,000 |
| Dec 2022 | 0 | -111,026,000 | -114,940,000 | 149,957,000 | 432,416,000 | — | -99,203,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMCR | Immunocore Holdings plc | $1.50B | $29.41 | — |
| IMTX | Immatics N.V. | $1.53B | $11.19 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.56B | $2.97 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.57B | $106.85 | — |
| VIR | Vir Biotechnology, Inc. | $1.58B | $9.38 | — |
News headlines (Yahoo Finance, 1h cache)
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
2026-05-17 19:13 · Yahoo
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts
2026-05-17 14:37 · Yahoo
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 21:15 · Yahoo
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
2026-05-12 20:01 · Yahoo
A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness
2026-05-12 02:10 · Yahoo
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
2026-05-07 12:32 · Yahoo
What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy
2026-04-26 15:13 · Yahoo
Maze Therapeutics Announces $150 Million Registered Offering
2026-04-22 04:09 · Yahoo
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact
2026-04-21 02:47 · Yahoo
Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks
2026-04-08 06:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.